We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Incase you missed it “Uniquely LiDCO will be the only western supplier of hemodynamic monitoring solutions that is manufacturing its product locally in China. This could be a key differentiator as the vast majority of the 22,000 hospitals in China can only procure domestically manufactured products. China is the second largest healthcare market in the world with a five-year compound annual growth rate by value of 17% compared with 4% in the United States1.”
US still big obviously we’ll find out soon, and note the press coverage, states are outbidding each other for medical equipment!
Trek
“Any idea of the running costs for each monitor per year? I think they have sold over 200 so far this year“
The unit costs are not published in the accounts but they cost much less to run than the revenue that the generate. This is compounded by the fact that the company has gone 0.3m ebitda positive and that is set to increase significantly. Imo.
Trek
Any idea of the running costs for each monitor per year? I think they have sold over 200 so far this year
“doubt company will remain independent for long”
Precisely who else puts two slides in a corporate presentation about M&A benchmarks. Plan here is max revenue from cv19 and sell for 7x revenue. Remember once the units are sold then in rolls the fixed rate fees for diagnostic and maintenance. All imo albeit pretty obvious!
Trek
Medical kit is flowing even in EU they have green lanes and even in Italy key factories are open. Check out DCTA last RNS, based in Milan. Don’t forget LID monitor remotely, staff don’t have to travel and this stuff is plug and play.
Trek
Do they realy make the best? They have limited stock and suppliers are in Singapore so can't get much out of there right now.
Demand for LIDCO’s monitors, particularly LIDCORapid will be surging on the back of COVID19 and not just in the U.K. Expect the shares to trike from here and doubt company will remain independent for long. They make the best kit.
Plenty of skin in game...
https://www.marketscreener.com/LIDCO-GROUP-PLC-4003523/company/
Trek
What is the % ownership from the executive board?
Corporate presentation dedicates 2 slides to M&A as being a way to recognise ‘true value’. It’s almost as if they are open to offers. 4-7 x revenues! 28m as is but FY guidance has been upped.
Their model is cheaper more efficient and can monitor across pts with software as a service. And perhaps most importantly “No need to increase infection risk by ‘breaking the line’” which is key for cv19,
Sales in China have rocketed (RNS) US and UK to follow (US was already up 47% enforce cv19) overall revenues up 115% before now, and buyers stay generating recurring revenue.
Cash £1.2m probably around £.75m and Zero debt! Revenues coming through following sales lag will imo be transformational as buyers like the product and stay.
What a little gem even without the cv19 boost.
Trek
http://www.lidco.com/wp-content/uploads/2020/02/Growth-Innovation-London-Feb-20-v2.pdf
Only a matter of time folks, this will gap up on news
I doesn’t matter if it’s a buy or sell at this point it’s volume that is important. The lse algorithm only works with a tighter spread. Any trade near the mid point can be miss reported even a sell as a buy. Matters not. Look a volume in March....
https://www.londonstockexchange.com/exchange/prices-and-markets/stocks/exchange-insight/trade-data.html?fourWayKey=GB0030546849GBGBXASX1
Trek
I would say that anything above 6.51 are buys, just shows you how they are playing this.
Those few buys show how quickly this one can move, wow! Shot above 7.00 for a brief second with a handful of buys.
Ah sorry, I see, buys showing as sells!
I think these are buys too?
09:54:38 24-Mar-2020 7.10 GBX 31,900 2,264.90
09:54:27 24-Mar-2020 7.00 GBX 31,900 2,233.00
10:02:01 6.80 21,883 1,488
This trade is a buy!!
Yes , they have exposure in the right markets, which is a plus.
I expect we will get an RNS soon enough saying there is an increase in demand in the US similar to the one the co released for China.
Remember these are the guys that make the ‘shovels in the gold rush’. The US cv19 numbers are going to be huge and they are already bidding county against county for pretty much all and any medical equipment. lidco’s technology is imo going to be in demand....
“The 19% growth in FY20 LiDCO product sales reflects growth in all regions compared with the prior year. LiDCO product sales grew by 28% in the USA to £1.8m (FY19: £1.4m), by 1% in the UK to £3.6m (FY19: £3.6m) and sales outside of the Company's direct markets were up 60% to £2.0m (FY19: £1.3m). The significant growth outside the UK included £0.4m growth in China from the launch of the new monitor and, as a result sales outside the UK now represent just over half (FY19: 43%) of LiDCO product sales.”
The US RNS will come as it will be material as you see from above it was ahead of China in sales volumes and cv19 volumes in the US will be higher than China. Stands to reason.
Then booom!
Oh guess what, once they buy this stuff there is recurring revenue, and they are already forecasting EBBIT positive! And results end of April!
Boom again!
Trek
The Brokers will negotiate a better price for the big investor, but it's the MMs who dictate. I reckon they were short of stock yesterday morning and profiteered from the sudden demand. Only pre holders to yesterday benefitted from the rise and the traders got caught.
Trouble is they're so far under the radar.
I wanted to buy this yesterday ,so when i called my broker as soons i said i wanted to buy this shoot up from 6 to 10,70 give you an idea what brokers are like ...
This appears to be shrewdly manipulated.
Retained most of today's rise, bodes well for the next bit of news!
Similar at SNG. It’s dropped to 52p. Topped up that as well !